|
市場調査レポート
商品コード
1772662
痙縮治療市場規模、シェア、成長分析、タイプ別、薬剤クラス別、エンドユーザー別、適応症別、投与経路別、地域別 - 産業予測、2025年～2032年Spasticity Treatment Market Size, Share, and Growth Analysis, By Type, By Drug Class, By End-user, By Indication, By Route Of Administration, By Region - Industry Forecast 2025-2032 |
||||||
|
|||||||
| 痙縮治療市場規模、シェア、成長分析、タイプ別、薬剤クラス別、エンドユーザー別、適応症別、投与経路別、地域別 - 産業予測、2025年～2032年 |
|
出版日: 2025年07月11日
発行: SkyQuest
ページ情報: 英文 162 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
痙縮治療の世界市場規模は2023年に15億米ドルと評価され、2024年の15億7,000万米ドルから2032年には23億1,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは4.9％で成長する見通しです。
世界の痙縮治療市場は、多発性硬化症や脳性麻痺などの神経疾患の有病率の上昇に牽引され、大きな成長を遂げています。利用可能な治療オプションに関する意識の高まりと、薬理学的および非薬理学的介入を含む治療法の進歩が、市場のダイナミクスを高めています。さらに、個別化医療に対する需要の高まりが、個々の患者のニーズに合わせた革新的な治療ソリューションの開発に影響を与えています。ヘルスケアプロバイダーと製薬企業の連携も研究開発を促進し、より効果的な治療法の導入につながっています。さらに、ヘルスケアのインフラ整備と治療へのアクセス向上を目的とした政府の取り組みが市場拡大を後押しし、より広範なヘルスケア展望の中で有望な分野となることが期待されています。
目次
イントロダクション
- 調査の目的
- 調査範囲
- 定義
調査手法
- 情報調達
- 二次と一次データの方法
- 市場規模予測
- 市場の前提条件と制限
エグゼクティブサマリー
- 世界市場の見通し
- 供給と需要の動向分析
- セグメント別機会分析
市場力学と見通し
- 市場概要
- 市場規模
- 市場力学
- 促進要因と機会
- 抑制要因と課題
- ポーターの分析
主な市場の考察
- 重要成功要因
- 競合の程度
- 主な投資機会
- 市場エコシステム
- 市場の魅力指数（2024年）
- PESTEL分析
- マクロ経済指標
- 価格分析
- ケーススタディ
痙縮治療市場規模：タイプ別& CAGR（2025-2032）
- 市場概要
- 薬物療法
- 理学療法
- 外科的治療
痙縮治療市場規模：薬剤クラス別& CAGR（2025-2032）
- 市場概要
- GABAアゴニスト
- α2アドレナリン作動薬
- ボツリヌス毒素
- その他の薬剤クラス
痙縮治療市場規模：エンドユーザー別& CAGR（2025-2032）
- 市場概要
- 病院
- 外来手術センター
- 在宅ケア環境
- 専門クリニック
- 診断センター
痙縮治療市場規模：適応症別& CAGR（2025-2032）
- 市場概要
- 脳性麻痺
- 多発性硬化症
- 外傷性脳損傷
- その他
痙縮治療市場規模：投与経路別& CAGR（2025-2032）
- 市場概要
- 経口
- 非経口
痙縮治療市場規模& CAGR：地域別（2025-2032）
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
- アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ
競合情報
- 上位5社の比較
- 主要企業の市場ポジショニング（2024年）
- 主な市場企業が採用した戦略
- 最近の市場動向
- 企業の市場シェア分析（2024年）
- 主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）
主要企業プロファイル
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Medtronic
- Pfizer Inc
- Ipsen Pharma
- UCB Pharma Ltd
- INMED PHARMACEUTICALS INC
- Orient Pharma
- Taj Pharmaceuticals Limited
- Johnson & Johnson Services, Inc.
- MediciNova, Inc.
- Sun Pharmaceutical Industries Ltd
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Merz Pharma
- Acorda Therapeutics, Inc.
結論と提言
Global Spasticity Treatment Market size was valued at USD 1.5 billion in 2023 and is poised to grow from USD 1.57 billion in 2024 to USD 2.31 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).
The global spasticity treatment market is witnessing significant growth, driven by the rising prevalence of neurological disorders such as multiple sclerosis and cerebral palsy. Increasing awareness regarding the available treatment options and advancements in therapies, including both pharmacological and non-pharmacological interventions, are enhancing market dynamics. Additionally, the growing demand for personalized medicine is influencing the development of innovative treatment solutions tailored to individual patient needs. The collaboration between healthcare providers and pharmaceutical companies is also fostering research and development, leading to the introduction of more effective therapies. Furthermore, government initiatives aimed at improving healthcare infrastructure and access to treatment are expected to bolster market expansion, making it a promising segment within the broader healthcare landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Spasticity Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Spasticity Treatment Market Segments Analysis
Global Spasticity Treatment Market is segmented by Type, Drug Class, End-user, Indication, Route Of Administration and region. Based on Type, the market is segmented into Drug therapy, Physical therapy and Surgical treatment. Based on Drug Class, the market is segmented into GABA Agonist, Alpha2-adrenergic Agonists, Botulinum Toxins and Other Drug Class. Based on End-user, the market is segmented into Hospitals, Ambulatory surgical centers, Home care settings, Specialty clinics and Diagnostic centers. Based on Indication, the market is segmented into Cerebral palsy, Multiple sclerosis, Traumatic brain injury and Others. Based on Route Of Administration, the market is segmented into Oral and Parenteral. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Spasticity Treatment Market
One of the primary factors propelling the spasticity treatment market is the rising incidence of neurological disorders, including conditions such as cerebral palsy, multiple sclerosis, and spasticity resulting from strokes. As these disorders become increasingly common worldwide, there is an escalating need for effective treatment options. This demand encompasses a range of therapies, including oral medications, physical rehabilitation, and the use of botulinum toxins, which are essential in managing symptoms. Consequently, this heightened focus on effective intervention strategies is significantly driving the expansion and development of the spasticity treatment market.
Restraints in the Global Spasticity Treatment Market
The Global Spasticity Treatment market faces significant challenges due to the high costs associated with various treatment options, particularly advanced therapies such as botulinum toxin injections and physical rehabilitation. Patients, particularly those in low-income regions, often struggle to access these essential treatments. Financial barriers, including limitations imposed by insurance coverage and substantial out-of-pocket expenses, further hinder patient access. These economic constraints not only impact individual patients but also contribute to a stagnation in the overall growth of the industry, as many potential users are unable to afford the necessary care for managing spasticity effectively.
Market Trends of the Global Spasticity Treatment Market
The Global Spasticity Treatment market is witnessing a significant shift towards the implementation of minimally invasive procedures, reflecting a broader trend in medical practices for improved patient outcomes. The adoption of intrathecal medication infusion devices and botulinum toxin injections has gained prominence among healthcare providers managing localized spasticity, as these techniques deliver effective temporary relief with reduced pain and quicker recovery times. This growing preference for less invasive options is not only enhancing patient comfort but also driving market growth, as advancements in technology and increasing awareness among healthcare professionals contribute to the rising demand for innovative spasticity management solutions.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Pricing Analysis
- Case Studies
Global Spasticity Treatment Market Size by Type & CAGR (2025-2032)
- Market Overview
- Drug therapy
- Physical therapy
- Surgical treatment
Global Spasticity Treatment Market Size by Drug Class & CAGR (2025-2032)
- Market Overview
- GABA Agonist
- Alpha2-adrenergic Agonists
- Botulinum Toxins
- Other Drug Class
Global Spasticity Treatment Market Size by End-user & CAGR (2025-2032)
- Market Overview
- Hospitals
- Ambulatory surgical centers
- Home care settings
- Specialty clinics
- Diagnostic centers
Global Spasticity Treatment Market Size by Indication & CAGR (2025-2032)
- Market Overview
- Cerebral palsy
- Multiple sclerosis
- Traumatic brain injury
- Others
Global Spasticity Treatment Market Size by Route Of Administration & CAGR (2025-2032)
- Market Overview
- Oral
- Parenteral
Global Spasticity Treatment Market Size & CAGR (2025-2032)
- North America (Type, Drug Class, End-user, Indication, Route Of Administration)
- US
- Canada
- Europe (Type, Drug Class, End-user, Indication, Route Of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Drug Class, End-user, Indication, Route Of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Drug Class, End-user, Indication, Route Of Administration)
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Drug Class, End-user, Indication, Route Of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- UCB Pharma Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- INMED PHARMACEUTICALS INC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Orient Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Taj Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MediciNova, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merz Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Acorda Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
